Fred Jacobs

Chief Executive Officer and Co-Founder
TYG Oncology
Nina E. Weisser
Fred started his career in healthcare working for a US Health Maintenance Organization. Fred has always believed that prevention and early diagnosis were as important as therapies for disease indications and has primarily worked in developing biomarkers and therapies for pancreatic cancer and other gastrointestinal cancers. Pancreatic cancer is predicted to become the Number 2 cancer killer in the US and our lead product, TYG100, has US Orphan Drug Designation for pancreatic cancer. TYG100 demonstrates the first application of Active Checkpoint Control Immunotherapy that induces our own natural polyclonal antibodies against two members of the gastrin family of hormones that comprise over 80% of the gastrin in our bodies.


No data was found